コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ls and loses the ability to help B cells for antibody production.
2 T-cell responses, as well as B-cell-mediated antibody production.
3 le antigen-specific mouse memory B cells for antibody production.
4 d inhibit Tfh-mediated B-cell activation and antibody production.
5 of bone marrow long-lived plasma cell (LLPC) antibody production.
6 o and to move into target tissues to support antibody production.
7 plasma cell generation and antigen-specific antibody production.
8 roduce energy and building blocks supporting antibody production.
9 entiate into plasma cells thereby leading to antibody production.
10 lling and increased B-cell proliferation and antibody production.
11 tions that could transform the technology of antibody production.
12 ased T-cell activation, thymic selection, or antibody production.
13 follicular helper T cell (TFH cell)-mediated antibody production.
14 hat the BiP cofactor Sil1 is dispensable for antibody production.
15 ly represses plasma cell differentiation and antibody production.
16 cessed antigen, was not sufficient to induce antibody production.
17 V reflected the specificity of high-affinity antibody production.
18 to diminished germinal center formation and antibody production.
19 ctivity, cell surface marker expression, and antibody production.
20 important role in many stages of therapeutic antibody production.
21 protein that suppresses B-cell function and antibody production.
22 ulates some aspects of B-cell activation and antibody production.
23 a suitable format for therapeutic monoclonal antibody production.
24 ndria, particularly in B-cell activation and antibody production.
25 leads to switch of the cellular response to antibody production.
26 , IL-5 and IL-13 and diminished OVA-specific antibody production.
27 aive B cells and how this relates to de novo antibody production.
28 signaling, cell survival, proliferation, and antibody production.
29 ysis, flow cytometry, suppression assay, and antibody production.
30 n of host follicular helper T cell-dependent antibody production.
31 at least in part) for the observed defect in antibody production.
32 d organ development, B cell development, and antibody production.
33 cells are critical for PF4/heparin-specific antibody production.
34 nteractor (TACI) often display dysfunctional antibody production.
35 cells require help from T cells to initiate antibody production.
36 ge of distinct immune deficiencies affecting antibody production.
37 ponses strongly correlated with neutralizing antibody production.
38 ly prevented donor-specific immunoglobulin M antibody production.
39 with significant implications in industrial antibody production.
40 ression of cellular host responsiveness, and antibody production.
41 of T-cell proliferation and T-cell-dependent antibody production.
42 l differentiation, resulting in dysregulated antibody production.
43 lymph nodes, with plasma cell formation and antibody production.
44 re of B-1a cells as well as regulating their antibody production.
45 ma cell maturation, and negligible antiviral antibody production.
46 at a CD4 level but is broken at the level of antibody production.
47 and consequent germinal center formation and antibody production.
48 ic immunity and NP-immune protection require antibody production.
49 icular B-cell migration and T-cell-dependent antibody production.
50 wide application in vaccine development and antibody production.
51 m immunoglobulin G, A, and/or M with loss of antibody production.
52 ect in the formation of germinal centers and antibody production.
53 days as indicated by a complete block of IgG antibody production.
54 l as the result of SV40 Tag immunization and antibody production.
55 tigen-specific whole immunoglobulin and thus antibody production.
56 colonize the bone marrow and do not sustain antibody production.
57 conjunction with increased antigen-specific antibody production.
58 ts as early as 18 days, suggesting antidonor antibody production.
59 respond to LCMV infection and support IgG2a antibody production.
60 otes B cell growth, survival and memory, and antibody production.
61 lls mediated in vivo suppression of anti-OVA antibody production.
62 activation, cytolytic effector function, and antibody production.
63 tokines (IL-17, TNFalpha, and IFNgamma), and antibody production.
64 work together to influence anti-factor VIII antibody production.
65 s in T-cell priming can dramatically perturb antibody production.
66 rget of therapy given their critical role in antibody production.
67 howed higher inflammatory response and lower antibody production.
68 y respond to infections with increased local antibody production.
69 rminal center formation and antigen-specific antibody production.
70 f the most critical steps in hapten-specific antibody production.
71 sadvantage to PCs for long-term survival and antibody production.
72 GC B cells, and high-affinity class-switched antibody production.
73 ted with a severe impairment in SIV-specific antibody production.
74 play critical roles in the regulation of IgE antibody production.
75 ntrol the GC reaction, along with pathogenic antibody production.
76 ng plasma cells (PCs) is vital for sustained antibody production.
77 lasma cells is required to sustain long-term antibody production.
78 cytic capacity was further enhanced after TI antibody production.
79 cialized in supporting B-cell maturation and antibody production.
80 for modulating the function of TFR cells and antibody production.
81 Tertiary lymphoid tissue formation and local antibody production add to intrarenal complement activat
82 t heart transplant recipients, normal anti-A antibody production after "A-into-O" piglet kidney trans
83 host lymphocytes and better T-cell-dependent antibody production after 1 Gy compared with 2 Gy TBI.
86 were independently associated with decreased antibody production after influenza vaccination in healt
88 erse events, serum arginine, AFP levels, and antibody production against ADI were measured on a regul
89 sing the NiNLP platform resulted in elevated antibody production against His-tagged influenza hemaggl
91 invasive S. pyogenes infection respond with antibody production against sHIP suggest a role for the
92 ting T and B cell frequencies, and increased antibody production against the SARS-CoV-2 spike protein
93 activation of plasma cells with significant antibody production already in ETR, followed by a cresce
94 es evidence of iNK T cell help for antilipid antibody production, an important aspect of infections,
95 tion, vaccination, and trauma with increased antibody production and a more T helper (Th)2-predominan
96 abling efficient knobs-into-holes bispecific antibody production and a robust path to generating high
97 720 specifically inhibited anti-MHC class II antibody production and abrogated macrophage infiltratio
100 ly subdominant to the head in terms of serum antibody production and antigen-specific B and Tfh cell
101 onsible primarily for the basic functions of antibody production and cell-mediated immune responses,
102 relationship between hemagglutinin-specific antibody production and changes in the size and characte
107 Freund's adjuvant (IFA), resulted in higher antibody production and earlier remyelination in SFV-inf
111 chanisms by which the PD-1 pathway regulates antibody production and help reconcile inconsistencies s
113 s of rat ECDI-SPs effectively prevented such antibody production and led to the indefinite survival o
114 ns in FCGR2B, which controls factors such as antibody production and macrophage activation, are impor
116 ay decrease sensitization and donor-specific antibody production and might improve outcomes in AMR, i
119 ovides a new target and strategy to modulate antibody production and responses with profound therapeu
121 ibody-expressing cells in facilitating local antibody production and severe nasal polyps in AERD.
122 developed a novel IL26 vaccine to stimulate antibody production and suppress IL26-enhanced engraftme
123 ole of long-lived plasma cells in persistent antibody production and the factors regulating their lon
126 clones with the highest purity of bispecific antibody production and the results significantly correl
129 in allergic immune responses, including IgE antibody production and type 2 cytokine-mediated inflamm
130 al burden for autoimmune disease or abnormal antibody production and were not enriched in the genetic
131 ction leads to enhanced local virus-specific antibody production and, thus, increased protection agai
132 activation: muMT strain (lacking B cells and antibody production) and intracerebroventricular injecti
133 o induce antigen-specific T cell activation, antibody production, and anti-tumor immunity in vivo, an
134 f tolerance can lead to PF4/heparin-specific antibody production, and B-cell tolerance may play an im
135 m B6.TC mice increased B cell proliferation, antibody production, and chemokine receptor expression a
136 te activities, adhesion molecule expression, antibody production, and cytokine and inflammatory media
137 mice displayed defective B cell maturation, antibody production, and formation of secondary lymphoid
138 tive influenza virus enhances virus-specific antibody production, and importantly, this effect is dep
141 globulin raised the platelet counts, reduced antibody production, and normalized the thymic and splen
142 VII collagen-immunized mice, suppressed auto-antibody production, and reduced dermal neutrophilic inf
143 s to germinal center (GC) B cells to support antibody production, and suppressive T-follicular regula
144 xtrafollicular antibody response, long-lived antibody production, and the emergence of public TCRbeta
145 cytes, their regulatory roles independent of antibody production, and the molecular events that make
146 ate multiple effector functions that include antibody production, antigen presentation to T cells, co
147 ate multiple effector functions that include antibody production, antigen presentation to T cells, co
148 early CD4(+) T cell response and HA-specific antibody production are associated with lowered viral ti
150 nor T-cell responses that support pathogenic antibody production are required for cGVHD development.
152 However, in contrast to deficient anti-A antibody production as seen long-term after "A-into-O" i
153 suggest an intrinsic B-lymphocyte defect in antibody production as well as an extrinsic defect in Ig
154 ulations during infection or decreased serum antibody production, as IL-6 KO mice had similar composi
156 H1)-like cells promote B cell activation and antibody production at levels indistinguishable from con
157 d myeloid signals to orchestrate innate-like antibody production at the interface between the immune
158 gosity has no effect on organ development or antibody production but prolongs the latency period and
159 NKT cells in SAP(-/-).BALB/c mice adjuvated antibody production, but not the germinal center reactio
160 minant theory implicates antigen-independent antibody production by a subset of long-lived plasma cel
161 functional defects, and decreased anti-dsDNA antibody production by autologous B cells in SLE patient
163 t CpG promotes pro-inflammatory cytokine and antibody production by B cells via the Toll-like recepto
167 tory pathways that enable continuous natural antibody production by B-1 cells, the main cellular sour
168 are a regulatory T cell subset that controls antibody production by inhibiting T follicular helper (T
170 dy responses that are characterized by rapid antibody production by marginal zone and B1 B cells.
171 LRBA-deficient TFH cells supported in vitro antibody production by naive LRBA-sufficient B cells.
172 tive B cells acquired the ability to inhibit antibody production by new naive B cells in an antigen-s
175 e able to inhibit lipopolysaccharide-induced antibody production by splenocytes in vitro, and kynuren
176 processes it enables, whether the process is antibody production by the immune system or tissue diffe
177 anisms is limited to thymus-independent (TI) antibody production by the marginal zone (MZ) B cells, l
181 del, potential effects of IL-17 cytokines on antibody production could be distinguished from critical
182 gulate several aspects of immunity including antibody production, cytokine secretion, and T-cell acti
183 ocytes derived from B-cell-deficient mice or antibody production-deficient mice were unable to effici
184 telomeric ODN suppress B-cell activation and antibody production demonstrating a natural mechanism fo
186 ependent B cell proliferation and short-term antibody production, development of long-term humoral im
187 er finding demonstrates that anti-glycolipid antibody production does not require cognate help from V
188 nal center (GC) B cells and antigen-specific antibody production during acute infection with lymphocy
189 mechanisms that drive B cell activation and antibody production during chronic airway inflammation.
191 e of a new mechanism by which IL-6 regulates antibody production during viral infection, and a novel
192 promise in cell surface marker expression or antibody production either in naive mice or in the conte
193 ch as bacterial persistence, drug discovery, antibody production, epigenetic biomarker analyses, etc.
194 passive infusion did not impair the de novo antibody production following HIV-1 Env vaccination.
195 VIII-deficient mouse model demonstrated that antibody production from FVIII-primed spleen cells in vi
197 lted in lower bacteremia, increased specific antibody production, higher production of CXCL13 and IL-
198 nstitute the only known cell type capable of antibody production; however, recent evidence supports a
199 te development but impaired T cell-dependent antibody production, IgG antibody affinity maturation, a
201 gnificantly reduced B-cell proliferation and antibody production in allogeneic culture (P<0.01 vs. co
204 of B cells to plasma cells and high affinity antibody production in germinal centers (GCs), and Tfh d
205 ere immune reaction with more than 100 times antibody production in group II compared with group I.
208 Here, we identified that, in addition to antibody production in lymphoid tissues, plasma cells re
209 nesis of allergies, and on the mechanisms of antibody production in memory B cell responses.IgE is an
210 tidis induces significant serum bactericidal antibody production in mice and is a candidate meningoco
213 that incites such prevalent anti-PF4/heparin antibody production in more than 50% of patients exposed
214 nasal polyps, but upstream drivers of local antibody production in nasal polyps are undetermined.
217 acquisition of adaptive immune responses and antibody production in response to foreign antigens.
218 by low serum immunoglobulin (Ig) M, low IgM antibody production in response to S pneumoniae followin
220 in Ig genes, and in vitro proliferation and antibody production in STAT3-HIES patients and healthy c
221 r T (T(FH)) cells that mediate high-affinity antibody production in tandem with the induction of long
222 SP90b1 ablation in B cells was an attenuated antibody production in the context of TLR stimulation.
223 ther molecular chaperone system was used for antibody production in the LPS-stimulated splenic B cell
224 ted MV with NDV led to increased MV-specific antibody production in the presence and absence of passi
228 at activate TLR2 and TLR4 restored long-term antibody production in ZBTB20-deficient chimeras through
229 y repressing plasma cell differentiation and antibody production, in addition to its opposing, active
230 tion, histological lesions, and neutralizing antibody production, indicating that this monkey model i
231 ates better understanding of the kinetics of antibody production induced by infection with SARS-CoV-2
233 actors but enhanced immunity with respect to antibody production, innate cytokines, and chemokines.
234 ti-myelin-oligodendrocyte glycoprotein (MOG) antibody production, interleukin (IL)-4, IL-8, IL-10, IL
239 bviral particles is high but either anti-HBV antibody production is fast, the antibody affinity is hi
243 allenge with PF4/heparin complexes, and that antibody production is severely impaired in B-cell-speci
245 idered to be T-cell independent, whereas IgE antibody production is thought to involve sequential cla
248 he time and costs associated with monoclonal antibody production limit the potential for portable dia
249 everity and onset of diarrhoea, OVA-specific antibody production, mast cell number and activity, infl
250 at the therapeutic intervention that reduces antibody production may prolong graft survival in transp
253 SV challenge was independent of neutralizing antibody production or cell-mediated adaptive immunity.
254 transplantation; however, therapy to control antibody production or to alter its impact on the allogr
255 inherited deficits in immune function (e.g., antibody production or type I IFN signaling), as well as
259 pha cytokine secretion by CD4(+) T cells and antibody production predominantly of IgG1 and IgG3 subcl
260 ing profiles eliciting >10-fold increases in antibody production relative to bolus vaccination post p
262 for over 2 months, and elicited anti-non-Gal antibody production remained suppressed for the duration
263 xamethasone increased B-cell populations and antibody production, signifying an increased humoral imm
264 -Ia, they might be useful in suppressing HLA antibody production, similar to the way anti-RhD Abs sup
267 se appears to be independent of cytokine and antibody production, suggesting modulation of antigen pr
268 s is followed by T and B cell proliferation, antibody production, T cell differentiation, and cytokin
272 CD4 T cells are needed for B cell-driven antibody production that leads to immune complex formati
273 a novel platform to inhibit antigen-specific antibody production that preserves the immune system's a
275 l, and eosinophil activation, as well as IgE antibody production, thus protecting against helminthes
276 do not establish the presence of intrathecal antibody production to B. burgdorferi and therefore shou
278 rive B cell proliferation, class switch, and antibody production to induce primary antigen-specific i
280 enerates sufficient antigen-specific humoral antibody production to protect from mucosal viral challe
282 itch, our study places IRF4 in the center of antibody production toward T-cell-dependent antigens.
283 C reactions that drive B cell maturation and antibody production, ultimately determining B cell fate.
284 elopment, and cellular mechanisms leading to antibody production versus immune tolerance to FVIII, ar
285 inct states, guiding immune responses toward antibody production via Tfh cells or inflammation by Tef
290 es and genetic polymorphisms predisposing to antibody production we serially monitored 24-hour protei
291 -/-)), and to distinguish this function from antibody production, we created transgenic (Tg) mice tha
295 ine inhibits T cell proliferation and alters antibody production, which are important components of a
296 hat ischemic renal injury leads to a rise in antibody production, which may be harmful to renal allog
297 might combine IL-21-mediated T-cell aid for antibody production while maintaining TH1 cytokine expre
298 esponse of B cells in vitro but also trigger antibody production with class switch recombination in v
299 iated with IgE, IgG, and IgG(4) anti-Bla g 5 antibody production, with a significant correlation betw
300 quely poised to promote B-cell responses and antibody production within pathologically inflamed non-l